Survival following URD BMT for CML3-150
| Relapse or Death . | RR (95% CI) . | P . |
|---|---|---|
| Chronic phase | 0.67 (0.59-0.77) | .0001 |
| Early BMT (≤12 mo) | 0.72 (0.61-0.84) | .0001 |
| Younger recipient (≤35 y) | 0.69 (0.60-0.80) | .0001 |
| Younger donor (≤35 y) | 0.91 (0.79-1.05) | .20 |
| HLA-match | 0.91 (0.79-1.05) | .32 |
| CMV seronegative recipient | 0.80 (0.70-0.92) | .002 |
| TBI | 0.97 (0.78-1.22) | .82 |
| Unmanipulated graft | 0.90 (0.74-1.10) | .31 |
| Grade 0/II acute GVHD | 0.36 (0.31-0.41) | .0001 |
| Relapse or Death . | RR (95% CI) . | P . |
|---|---|---|
| Chronic phase | 0.67 (0.59-0.77) | .0001 |
| Early BMT (≤12 mo) | 0.72 (0.61-0.84) | .0001 |
| Younger recipient (≤35 y) | 0.69 (0.60-0.80) | .0001 |
| Younger donor (≤35 y) | 0.91 (0.79-1.05) | .20 |
| HLA-match | 0.91 (0.79-1.05) | .32 |
| CMV seronegative recipient | 0.80 (0.70-0.92) | .002 |
| TBI | 0.97 (0.78-1.22) | .82 |
| Unmanipulated graft | 0.90 (0.74-1.10) | .31 |
| Grade 0/II acute GVHD | 0.36 (0.31-0.41) | .0001 |
BMT = bone marrow transplant; CI = confidence interval; CML = chronic myelogenous leukemia; CMV = cytomegalovirus; GVHD = graft-versus-host disease; RR = relative risk; TBI = total body irradiation; URD = unrelated donor.
Favorable factors associated with a lower relative risk of death are shown. Acute GVHD was considered as a time-dependent co-variate.